Cargando…

Prominent Hyperproinsulinemia in a Middle Age Patient

INTRODUCTION: Insulin is synthesized in the β-cells from preproinsulin. Preproinsulin becomes proinsulin after leaving the signal peptide. Proinsulin is separated into C-peptide and insulin by 2 enzymes. Hyperproinsulinemia is suspected to be a pancreatic β-cell defect that is augmented by the incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Hiroshi, Kawakami, Kyoko, Yoshino, Kei, Yoshino, Gen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414601/
https://www.ncbi.nlm.nih.gov/pubmed/34483693
http://dx.doi.org/10.1177/11795476211042241
_version_ 1783747810928099328
author Yoshino, Hiroshi
Kawakami, Kyoko
Yoshino, Kei
Yoshino, Gen
author_facet Yoshino, Hiroshi
Kawakami, Kyoko
Yoshino, Kei
Yoshino, Gen
author_sort Yoshino, Hiroshi
collection PubMed
description INTRODUCTION: Insulin is synthesized in the β-cells from preproinsulin. Preproinsulin becomes proinsulin after leaving the signal peptide. Proinsulin is separated into C-peptide and insulin by 2 enzymes. Hyperproinsulinemia is suspected to be a pancreatic β-cell defect that is augmented by the increased demand placed on the β-cell by hyperglycemia. CASE PRESENTATION: A 39-year-old Japanese man visited to Shin-suma hospital in May 2013. Liver dysfunction, dyslipidemia, and hyperuricemia had been found in medical checkups in his workplace. Therefore, he visited Shin-suma hospital in order to receive intensive examination. Diet and exercise therapy were initiated. In November 2013, intact proinsulin and proinsulin per insulin (PI/I) ratio were evaluated as part of an ongoing study. His intact proinsulin level and PI/I ratio were markedly elevated. A 75 g oral OGTT revealed that his glucose tolerance was impaired. His glycosylated hemoglobin was 6.9%. He was diagnosed as having type 2 diabetes mellitus. Although, diet and exercise therapy continued, his hyperproinslinemia and diabetes mellitus remained. Therefore, aloguliptin was started in order to recover insulin secretion in November 2014. Thereafter, pioglitazone was added to improve insulin resistance. Finally, luseogliflozin was commenced to expect glucose-lowering effects. His HbA1c was stabilized. To the best of our knowledge, there have been few reports of patients with hyperproinsulinemia. CONCLUSION: When the physicians face treatment resistance in diabetes mellitus, we emphasize that evaluation of proinsulin should be considered as one of the methods.
format Online
Article
Text
id pubmed-8414601
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-84146012021-09-04 Prominent Hyperproinsulinemia in a Middle Age Patient Yoshino, Hiroshi Kawakami, Kyoko Yoshino, Kei Yoshino, Gen Clin Med Insights Case Rep Case Report INTRODUCTION: Insulin is synthesized in the β-cells from preproinsulin. Preproinsulin becomes proinsulin after leaving the signal peptide. Proinsulin is separated into C-peptide and insulin by 2 enzymes. Hyperproinsulinemia is suspected to be a pancreatic β-cell defect that is augmented by the increased demand placed on the β-cell by hyperglycemia. CASE PRESENTATION: A 39-year-old Japanese man visited to Shin-suma hospital in May 2013. Liver dysfunction, dyslipidemia, and hyperuricemia had been found in medical checkups in his workplace. Therefore, he visited Shin-suma hospital in order to receive intensive examination. Diet and exercise therapy were initiated. In November 2013, intact proinsulin and proinsulin per insulin (PI/I) ratio were evaluated as part of an ongoing study. His intact proinsulin level and PI/I ratio were markedly elevated. A 75 g oral OGTT revealed that his glucose tolerance was impaired. His glycosylated hemoglobin was 6.9%. He was diagnosed as having type 2 diabetes mellitus. Although, diet and exercise therapy continued, his hyperproinslinemia and diabetes mellitus remained. Therefore, aloguliptin was started in order to recover insulin secretion in November 2014. Thereafter, pioglitazone was added to improve insulin resistance. Finally, luseogliflozin was commenced to expect glucose-lowering effects. His HbA1c was stabilized. To the best of our knowledge, there have been few reports of patients with hyperproinsulinemia. CONCLUSION: When the physicians face treatment resistance in diabetes mellitus, we emphasize that evaluation of proinsulin should be considered as one of the methods. SAGE Publications 2021-09-01 /pmc/articles/PMC8414601/ /pubmed/34483693 http://dx.doi.org/10.1177/11795476211042241 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Yoshino, Hiroshi
Kawakami, Kyoko
Yoshino, Kei
Yoshino, Gen
Prominent Hyperproinsulinemia in a Middle Age Patient
title Prominent Hyperproinsulinemia in a Middle Age Patient
title_full Prominent Hyperproinsulinemia in a Middle Age Patient
title_fullStr Prominent Hyperproinsulinemia in a Middle Age Patient
title_full_unstemmed Prominent Hyperproinsulinemia in a Middle Age Patient
title_short Prominent Hyperproinsulinemia in a Middle Age Patient
title_sort prominent hyperproinsulinemia in a middle age patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414601/
https://www.ncbi.nlm.nih.gov/pubmed/34483693
http://dx.doi.org/10.1177/11795476211042241
work_keys_str_mv AT yoshinohiroshi prominenthyperproinsulinemiainamiddleagepatient
AT kawakamikyoko prominenthyperproinsulinemiainamiddleagepatient
AT yoshinokei prominenthyperproinsulinemiainamiddleagepatient
AT yoshinogen prominenthyperproinsulinemiainamiddleagepatient